Top

Published in:

01-11-2011 | Original Article

Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin

Authors: Hui Li, Hua Zhao, Jinpu Yu, Yanjun Su, Shui Cao, Xiumei An, Xiubao Ren

Published in: Cancer Immunology, Immunotherapy | Issue 11/2011

Abstract

Expansion of CD4+CD25+ regulatory T cells (Tregs) in tumor microenvironment was one of the mechanisms by which cancer cells escaped host defense. Thymic stromal lymphopoietin (TSLP) contributes to the generation of natural Tregs in thymus. Therefore, the purpose of this report was to investigate the role of TSLP in the increasing prevalence of Tregs in lung cancer microenvironment. The expression ratio of TSLP protein in tumor tissues was significantly increased compared with that in benign lesion and non-cancer lung tissue. The prevalence of Tregs in tumor microenvironment was correlated with the expression of TSLP in lung cancer. Dendritic cells (DCs) were induced from peripheral blood mononuclear cells (PBMCs) collected from lung cancer patients and left unstimulated (imDCs) or exposed to hTSLP (TSLP-DCs) or LPS (LPS-DCs). TSLP-DCs expressed intermediate levels of CD83 and high levels of CD86, CD11C, and HLA-DR, which showed a characteristic of less mature DCs. TSLP-DCs secreted low levels of IL-6, IL-12, IL-10, TNF-α and IFN-γ, and high levels of TGF-β and MDC. The percentage of Tregs in CD4+CD25− T cells cocultured with TSLP-DCs group was statistically higher than that of LPS-DCs and imDCs. Transwell assays showed that TSLP-DCs exhibited increased ability to attract the migration of CD4+CD25− Tregs, when compared with imDCs. These results indicated that TSLP proteins were expressed in lung tumor tissue and correlated with the prevalence of Tregs. TSLP-DCs could induce CD4+CD25− T cells to differentiate into CD4+CD25+foxp3+ T cells and the migration of CD4+CD25+ T cells.

Ohara M, Yamaguchi Y, Matsuura KM et al (2009) Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol Immunother 58(3):441–447

Li L, Chao QG, Ping LZ et al (2009) The prevalence of FOXP3+ regulatory T-cells in peripheral blood of patients with NSCLC. Cancer Biother Radiopharm 24(3):357–367PubMedCrossRef

Tokuno K, Hazama S, Yoshino S et al (2009) Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer. Anticancer Res 29(5):1527–1532PubMed

Strauss L, Bergmann C, Szczepanski M et al (2007) A unique subset of CD4⁺CD25^highFoxp3⁺ T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13(15):4345–4354

Daniel J, Campbell DJ, Koch MA (2011) Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 11:119–130CrossRef

Liu VC, Wong LY, Jang T et al (2007) Tumor evasion of the immune system by converting CD4+CD25− T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178(5):2883–2892PubMed

Banerjee DK, Dhodapkar MV, Matayeva E et al (2006) Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108(8):2655–2661PubMedCrossRef

Watanabe N, Wang YH, Lee HK et al (2005) Hassall’s corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 436:1181–1185PubMedCrossRef

Lee JY, Lim YM, Park MJ et al (2008) Murine thymic stromal lymphopoietin promotes the differentiation of regulatory T cells from thymic CD4(+)CD8(−)CD25(−) naive cells in a dendritic cell-independent manner. Immunol Cell Biol 86:206–213

10.

Ito T, Wang YH, Duramad O et al (2005) TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 202(9):1213–1223

11.

Vosshenrich CA, Cumano A, Müller W et al (2004) Pre-B cell receptor expression is necessary for thymic stromal lymphopoietin responsiveness in the bone marrow but not in the liver environment. Proc Natl Acad Sci USA 101:11070–11075PubMedCrossRef

12.

Ramalingam TR, Pesce JT, Mentink-Kane MM et al (2009) Regulation of helminth-induced Th2 responses by thymic stromal lymphopoietin. J Immunol 182(10):6452–6459PubMedCrossRef

13.

Li YL, Li HJ, Ji F et al (2010) Thymic stromal lymphopoietin promotes lung inflammation through activation of dendritic cells. J Asthma 47(2):117–123PubMedCrossRef

14.

Soumelis V, Reche PA, Kanzler H et al (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3:673–680PubMedCrossRef

15.

Liu YJ, Soumelis V, Watanabe N et al (2007) TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol 25:193–219

16.

Fan H, Wang J, Zhou X et al (2009) Induction of antigen-specific immune tolerance by TGF-beta induced CD4⁺foxp3⁺ regulatory T cells. Int J Clin Exp Med 2(3):212–220PubMed

17.

Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798–809PubMedCrossRef

18.

Adach A, Ellert-Miklaszewska A, Kaminska B (2009) Molecular characterization of STAT signaling in inflammation and tumorigenesis. Methods Mol Biol 512:265–278PubMedCrossRef

19.

Bensinger SJ, Walsh PT, Zhang J et al (2004) Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol 172(9):5287–5296PubMed

20.

Hanabuchi S, Ito T, Park WR et al (2010) Thymic stromal lymphopoietin-activated plasmacytoid dendritic cells induce the generation of FOXP3+ regulatory T cells in human thymus. J Immunol 184(6):2999–3007PubMedCrossRef

21.

Gobert M, Treilleux I, Bendriss-Vermare N et al (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69(5):2000–2009PubMedCrossRef

22.

Qin XJ, Shi HZ, Deng JM et al (2009) CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin Cancer Res 15(7):2231–2237PubMedCrossRef

Title: Increased prevalence of regulatory T cells in the lung cancer microenvironment: a role of thymic stromal lymphopoietin
Authors: Hui Li
Hua Zhao
Jinpu Yu
Yanjun Su
Shui Cao
Xiumei An
Xiubao Ren
Publication date: 01-11-2011
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 11/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1059-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2011

Dual biological effects of the cytokines interleukin-10 and interferon-γ

Priming with very low-affinity peptide ligands gives rise to CD8+ T-cell effectors with enhanced function but with greater susceptibility to transforming growth factor (TGF)β-mediated suppression

Vaccination of patients with cutaneous melanoma with telomerase-specific peptides

“Tumor immunology meets oncology (TIMO) VII” from 15th to 16th of April 2011 in Halle/Saale, Germany

Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma

Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™

Keynote webinar | Spotlight on antibody–drug conjugates in cancer